IP Library › Patent Application 18478483
Patent Application
App. No. 18/478,483

COMBINATION THERAPY FOR TREATING CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/478,483
Abstract

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Claims (18)

1 . A method for treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of:

an EZH2 inhibitor and one or more VEGF/VEGFR inhibitors: or

the EZH2 inhibitor and one or more glucocorticoid receptor agonists (GRags);

wherein the EZH2 inhibitor is Compound 44 having the formula:

or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the cancer is resistant to VEGF/VEGFR inhibitor treatment.

3 . (canceled)

4 . The method for treating cancer of claim 1 comprising administering a therapeutically effective amount of the EZH2 inhibitor and one or more VEGF/VEGFR inhibitors.

5 . The method of claim 1 , wherein the cancer is resistant to EZH2 inhibitor treatment.

6 - 10 . (canceled)

11 . The method of claim 1 , wherein the one or more VEGF/VEGFR inhibitors are selected from bevacizumab (Avastin); sorafenib (Nexavar); sunitinib (Sutent); ranibizumab; pegaptanib; vandetinib; E7080; Zd6474; PKC-412; Vatalanib (Ptk787 or ZK222584); and motesanib diphosphate.

12 . The method of claim 1 , wherein the one or more VEGF/VEGFR inhibitors includes sunitinib.

13 . The method of claim 1 , wherein the EZH2 inhibitor and the one or more glucocorticoid receptor agonists (GRags) administered simultaneously or sequentially.

14 . The method of claim 1 , wherein the EZH2 inhibitor is administered prior to administration of the one or more glucocorticoid receptor agonists (GRags).

15 . The method of claim 1 , wherein the EZH2 inhibitor and the one or more VEGF/VEGFR inhibitors are administered simultaneously or sequentially.

16 . The method of claim 1 , wherein the EZH2 inhibitor is administered prior to administration of the one or more VEGF/VEGFR inhibitors.

17 . The method of claim 1 , wherein the cancer is a Non-Hodgkin's Lymphoma (NHL).

18 . The method of claim 1 , wherein the cancer is follicular lymphoma (FL).